US ANTIBIOTICS announced its subsidiary has received FDA approval for antibiotic compound NDA050564, a backlog item dating back to August 1984, which the company asserts clears the path for launching assets immediately. This regulatory milestone significantly alleviates specific inventory constraints and positions US ANTIBIOTICS to rapidly capitalize on current market demand for essential therapies.